United States - English - NLM (National Library of Medicine)

leader/cardinal health 110, inc. - camphor (synthetic) (unii: 5tjd82a1et) (camphor (synthetic) - unii:5tjd82a1et) - cough suppressant temporarily relieves cough ocurring with a cold

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 17751 - bone matrix implant, synthetic - the performances of the synthetic bone substitute are the filling of bone defects and the bony ingrowth from local osseous tissue onto the surface of the product (osteoconduction process). the total resorption of the product depends on numerous factors such as its size and volume, the location of the defect, the surgical technique, the health status of the patient. the bone reconstruction time is always inferior to the total resorption time. the synthetic bone substitute is intended for use to reconstruct bony voids or bone gaps of the skeletal system (e.g. extremities, spine and pelvis).

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - estrogens, conjugated synthetic a (unii: jm2621p2ls) (estrogens, conjugated synthetic a - unii:jm2621p2ls) - estrogens, conjugated synthetic a 0.45 mg - cenestin therapy is indicated for the: 1. treatment of moderate-to-severe vasomotor symptoms associated with the menopause. - 0.45 mg cenestin - 0.625 mg cenestin - 0.9 mg cenestin - 1.25 mg cenestin 2. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - 0.3 mg cenestin cenestin should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or a history of these conditions. - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). - liver dysfunction or disease. - cenestin therapy should not be used in patients with known hypersensitivity to its ingredients. - known or su

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - estrogens, conjugated synthetic b (unii: 8l6lak9btr) (estrogens, conjugated synthetic b - unii:8l6lak9btr) - estrogens, conjugated synthetic b 0.9 mg - enjuvia tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with menopause. - treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. when prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered. enjuvia tablets should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or a history of these conditions. - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). - liver dysfunction or disease. - known hypersensitivity to the ingredients of enjuvia tablets. - known or suspected pregnancy. there is no indication for enjuvia in pregnancy

Australia - English - Department of Health (Therapeutic Goods Administration)

precision surgical pty ltd - 17751 - bone matrix implant, synthetic - udesis gel contains porous resorbable btcp granules that create an osteoconductive scaffold for new bone growth. the granules are constructed of highly pure beta-tricalcium phosphate suspended in an aqueous polymer. the gel should be implanted directly into bony voids or defects of the skeletal system. the water soluble carrier gel then dissolves leaving behind the calcium phosphate matrix which is resorbed and replaced with bone during the healing process. udesis gel is intended to be used as a synthetic bone void filler. it is only indicated for filling and/or augmenting bone void or gaps that are not intrinsic to the stability of the bone structure, i.e. subjected to low load or compressive loading. if osseous defects are intrinsic to the stability or integrity of the skeleton, mechanical stability must be addressed prior to use. udesis indicated for use in place of corticocancellous, or cancellous or autograft bone. typical applications for bone substitutes are: bone void filling following surgery, typic

Australia - English - Department of Health (Therapeutic Goods Administration)

osstem australia pty ltd - 47971 - dental bone matrix implant, synthetic - q-oss+ performs the role of structural supporter for new bone, and accelerates the generation of new bone. interconnected micropores increase the bone substitute's surface area and solubility, as well as the resultant formation of biological apatite. the adjusted particle shape acts as macropores to facilitate body-fluid penetration, cell migration, and blood-vessel formation which progressively resorbed at the site of bone defects and allows the prompt regeneration of new bone. synthetic bone substitute that can be used for bone transplantations in the field of dentistry, for the purpose of restoration and reinforcement of bone defects.

Australia - English - Department of Health (Therapeutic Goods Administration)

more group pty ltd - 17751 - bone matrix implant, synthetic - synthetic bone replacement of bone for surgery and implantology surgical bone grafting,the product is a mixture of ha/tcp (60:40 or 20:80). the synthetic bone substitutes are available in various shapes and sizes in order to fill various bone defects

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - synthetic latex; alcohol ethoxylate - liquid - synthetic latex ungrouped active 450.0 g/l; alcohol ethoxylate emulsifiers & surfactants active 100.0 g/l - adjuvant - agricultural chemical additive | spray activator | spreading agent | wetting agent - extender/sticker/spreader | tank mixing | additive | agricultural chemical | herbicide | minimise antagonism | spray tank

United States - English - NLM (National Library of Medicine)

select brand - camphor (synthetic) (unii: 5tjd82a1et) (camphor (synthetic) - unii:5tjd82a1et) - camphor (synthetic) .623 g in 10 ml - cough suppressant temporarily relieves cough ocurring with a cold

United States - English - NLM (National Library of Medicine)

neopharm co., ltd. - camphor (synthetic) (unii: 5tjd82a1et) (camphor (synthetic) - unii:5tjd82a1et), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a), methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz) - camphor (synthetic) 4 g in 100 g - purpose topical analgesic uses temporarily relieves the minor aches and pains of muscles and joints associated with: - simple backache - arthritis - strains - bruises - sprains